Peptide-receptor ligands and multivalent approach

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 5, 2012, Pages 416-427

  Ruzza, Paolo ^a   Marchiani, Anna ^a,b   Antolini, Nicola ^a,b   Calderan, Andrea ^a  

^a CNR   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Multivalent approach; Peptide receptors; Tumour imaging

Indexed keywords

ALPHA INTERMEDIN; BETA INTERMEDIN; BOMBESTIN; CALCITONIN; CHELATING AGENT; CHOLECYSTOKININ OCTAPEPTIDE; CORTICOTROPIN; DEMOBESIN 1 TC 99M; DEMOTATE; DEPREOTIDE; GAMMA INTERFERON; GAMMA INTERMEDIN; GASTRIN DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GONADORELIN RECEPTOR; INTEGRIN RECEPTOR; MELANOCORTIN; NEUROMEDIN B; NEUROTENSIN DERIVATIVE; NEUROTESIN; OCTREOTIDE[3 TYROSINE]; PENTETIC ACID; PENTETREOTIDE; PENTETREOTIDE IN 111; PEPTIDE DERIVATIVE; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE;

BINDING AFFINITY; CANCER THERAPY; COMBINATORIAL CHEMISTRY; DIAGNOSTIC IMAGING; DRUG HALF LIFE; DRUG TARGETING; HUMAN; NEUROENDOCRINE TUMOR; NONHUMAN; PEPTIDE SYNTHESIS; PHAGE DISPLAY; RECEPTOR BINDING; REVIEW;

EID: 84861657016     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800617849     Document Type: Review

References (143)

1. Weiner, R.; Thakur, M. In Radionuclide peptide cancer therapy. Chinol M., Paganelli G., Eds., Taylor & Francis: New York (NY) 2006, 41-85.
2. Weiner, R.E.; Thakur, M.L. Radiolabeled peptides in diagnosis and therapy of oncological diseases. Appl. Radiat. Isotop., 2002, 57, 749-763.
3. Virgolini, I.; Traub, T.; Leimer, M.; Novotny, C.; Pangerl, T.; Ofluoglu, S.; Halvadjieva, E.; Smith-Jones, P.; Flores, J.; Li, S.R.; Angelberger, P.; Havlik, E.; Andreae, F.; Raderer, M.; Kurtaran, A.; Niederle, B.; Dubczak, R. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q. J. Nucl. Med., 2000, 44, 50-58.
4. Virgolini, I.; Traub, T.; Novotny, C.; Leimer, M.; Fuger, B.; Li, S.R.; Patri, P.; Pangerl, T.; Angelberger, P.; Raderer, M.; Andreae, F.; Kurtaran, A.; Dudczak, R. New trends in peptide receptor radioligands. Q. J. Nucl. Med., 2001, 45, 153-159.
5. Benedetti, E.; Morelli, G.; Accardo, A.; Mansi, R.; Tesauro, D.; Aloj, L. Criteria for the desing and biological characterization of radiolabeled peptide based pharmaceuticals. Biodrugs, 2004, 18, 279-295.
6. Aloj, L.; Morelli, G. Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy. Curr. Pharm. Des., 2004, 10, 3009-3031.
7. Lee, S.; Xie, J.; Chen, X. Peptide-based Probes for Targeted Molecular Imaging. Biochemistry, 2010, 49, 1364-1376.
8. Mammen, M.; Choi, S.K.; Whitesides, G.M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed., 1998, 37, 2755-2794.
9. Handl, H.L.; Vagner, J.; Han, H.; Mash E.; Hruby, V.J.; Gillies, R.J. Hitting multiple targets with multimeric ligands. Expert Opin. Ther. Targets, 2004, 8, 565-586.
10. Schottelius, M.; Wester, H.J. Molecular imaging targeting peptide receptors. Methods, 2009, 48, 161-177.
11. Okarvi, S.M. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med. Res. Rev., 2004, 24, 357-397.
12. Dijkgraaf, I.; Boerman, O.C.; Oyen, W.J.; Corstens, F.H.; Gotthardt, M. Development and application of peptide-based radiopharmaceuticals. Anticancer Agents Med. Chem., 2007, 7, 543-551.
13. Bodei, L.; Paganelli, G.; Mariani, G. Receptor radionuclide therapy of tumours: a road from basic research to clinical applications. J. Nucl. Med., 2006, 47, 375-377.
14. Waser, B.; Tamma, M.L.; Cescato, R.; Maecke, H.R.; Reubi, J.C. Highly efficient in vivo agonist-induced internalization of SST2 receptors in somatostatin target tissues. J. Nucl. Med., 2009, 50, 936-941.
15. Ginj, M.; Zhang, H.W.; Waser, B.; Cescato, R.; Wild, D.; Wang, X.J.; Erchegyi, J.; Rivier, J.; Macke, H.R.; Reubi, J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumours. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 16436-16441.
16. Cescato, R.; Maina, T.; Nock, B.; Nikolopoulou, A.; Charalambidis, D.; Piccand, V.; Reubi, J.C. Bombesin receptor antagonists may be preferable to agonists for tumour targeting. J. Nucl. Med. 2008, 49, 318-326.
17. Abd-Elgaliel, W.R.; Gallazzi, F.; Garrison, J.C.; Rold, T.L.; Sieckman, G.L.; Figueroa, S. D.; Hoffman, T.J.; Lever, S.Z. Design, synthesis, and biological evaluation of an antagonistbombesin analogue as targeting vector. Bioconjugate Chem., 2008, 19, 2040-2048.
18. Mansi, R.; Wang, X.J.; Forrer, F.; Kneifel, S.; Tamma, M.L.; Waser, B.; Cescato, R.; Reubi, J.C.; Maecke, H.R. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin. Cancer Res., 2009, 15, 5240-5249.
19. Mansi, R.; Wang, X.J.; Forrer, F.; Waser, B.; Cescato, R.; Graham, K.; Borkowski, S.; Reubi, J.C.; Maecke, H.R. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur. J. Nucl. Med. Mol. Imaging, 2011, 38, 97-107.
20. Cuttitta, F.; Carney, D.N.; Mulshine, J.; Moody, T.W.; Fedorko, J.; Fischler, A.; Minna, J.D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature, 1985, 316, 823-826.
21. Reubi, J.C.; Gugger, M.; Waser, B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 855-862.
22. Reubi, J.C.; Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 781-793.
23. Zhang, H.W.; Chen, J.H.; Waldherr, C.; Hinni, K.; Waser, B.; Reubi, J.C.; Maecke, H.R. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumours. Cancer Res., 2004, 64, 6707-6715.
24. Fields, G.B. In Solid-Phase Peptide Synthesis. Methods in Enzymology, Vol. 289 Academic Press: New York, 1997.
25. Fichna, J.; Janecka, A. Synthesis of Target-Specific Radiolabeled Peptides for Diagnostic Imaging. Bioconjugate Chem., 2002, 14, 3-17.
26. Akizawa, H.; Arano, Y.; Uezono, T.; Ono, M.; Fujioka, Y.; Uehara, T.; Yokoyama, A.; Akaji, K.; Kiso, Y.; Koizumi, M.; Saji, H. Renal metabolism of In-111-DTPA-D-Phe(1)-octreotide in vivo. Bioconjugate Chem., 1998, 9, 662-670.
27. Boerman, O.C.; Oyen, W.J.G.; Corstens, F.H.M. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumour and saving the kidney. Eur. J. Nucl. Med., 2001, 28, 1447-1449.
28. Mankoff, D.A.; Link, J.M.; Linden, H.M.; Sundararajan, L.; Krohn, K.A. Tumour receptor imaging. J. Nucl. Med., 2008, 49, 149S-163S.
29. Lamberts, S.W.J.; Bakker, W.H.; Reubi, J.C.; Krenning, E.P. Somatostatin-receptor imaging in the localization of endocrine tumours. N. Engl. J. Med., 1990, 323, 1246-1249.
30. Arano, Y.; Akizawa, H.; Uezono, T.; Akaji, K.; Ono, M.; Funakoshi, S.; Koizumi, M.; Yokoyama, A.; Kiso, Y.; Saji, H. Conventional and high-yield synthesis of DTPA-conjugated peptides: Application of a monoreactive DTPA to DTPA-DPhe(1)-octreotide synthesis. Bioconjugate Chem., 1997, 8, 442-446.
31. 111In-labeled somatostatin analogues for tumour scintigraphy and radionuclide therapy. Cancer Res., 1998, 58, 437-441.
32. Boerman, O.C.; Oyen, W.J.G.; Corstens, F.H.M. Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. Semin. Nucl. Med., 2000, 30, 195-208.
33. Lugtenburg, P.J.; Lowenberg, B.; Valkema, R.; Oei, H.Y.; Lamberts, S.W.; Eijkemans, M.J.; van Putten, W.L.; Krenning, E.P. Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas. J. Nucl. Med., 2001, 42, 222-229.
34. Seregni, E.; Chiti, A.; Bombardieri, E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur. J. Nucl. Med., 1998, 25, 639-658.
35. Bolzati, C.; Refosco, F.; Marchiani, A.; Ruzza, P. Tc-99m-Radiolabelled Peptides for Tumour Imaging: Present and Future. Curr. Med. Chem., 2010, 17, 2656-2683.
36. Rehfeld, J.F. Cholecystokinin. Best Pract. Res. Clin. Endocrinol. Metab., 2004, 18, 569-586.
37. Reubi, J.C.; Schaer, J.C.; Waser, B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumours. Cancer Res., 1997, 57, 1377-1386.
38. Behr, T.M.; Jenner, N.; Behe, M.; Angerstein, C.; Gratz, S.; Raue, F.; Becker, W. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumours. J. Nucl. Med., 1999, 40, 1029-1044.
39. Borin, G.; Calderan, A.; Ruzza, P.; Moroder, L.; Gohring, W.; Boverman, G.; Wunsch, E. Synthesis of human [15-norleucine]littlegastrin-II and des-1-tryptophan-[12-norleucine]minigastrin-II. Biol. Chem. Hoppe-Seyler, 1987, 368, 1363-1372.
40. Said, S.I.; Mutt, V. Polypeptide with broad biological activity-isolation from small intestine. Science, 1970, 169, 1217-1218.
41. Schwartz, C.J.; Kimberg, D.V.; Sheerin, H.E.; Field, M.; Said, S.I. Vasoactive intestinal peptide stimulation of adenylate cyclase and active electrolyte secretion in intestinal-mucosa. J. Clin. Invest., 1974, 54, 536-544.
42. Reubi, J.C. In vitro identification of VIP receptors in human tumours: potential clinical application. Ann. N.Y. Acad. Sci., 1996, 805, 753-759.
43. Fischman, A.J.; Babich, J.W.; Strauss, H.W. A ticket to ride-Peptide radiopharmaceuticals. J. Nucl. Med., 1993, 34, 2253-2263.
44. 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumours of the gastrointestinal tract. Nucl. Med. Biol., 1996, 23, 685-692.
45. Reubi, J.C. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q. J. Nucl. Med., 1997, 41, 63-70.
46. Virgolini, I.; Raderer, M.; Kurtaran, A.; Angelberger, P.; Banyai, S.; Yang, Q.; Li, S.; Banyai, M.; Pidlich, J.; Niederle, B.; Scheithauer, W.; Valent, P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumours. N. Engl. J. Med., 1994, 331, 1116-1121.
47. Reubi, J.C. In vitro identification of vasoactive-intestinal-peptide receptors in human tumours-implications for tumour imaging. J. Nucl. Med., 1995, 36, 1846-1853.
48. Langer, M.; Beck-Sickinger, A.G. Peptides as carrier for tumour diagnosis and treatment. Curr. Med. Chem. Anticancer Agents, 2001, 1, 71-93.
49. Vincent, J.P. Neurotensin receptors: binding properties, transduction pathways, and structure. Cell. Mol. Neurobiol., 1995, 15, 501-512.
50. Reubi, J.C.; Waser, B.; Schaer, J.C.; Laissue, J.A. Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas. Int. J. Cancer, 1999, 82, 213-218.
51. Reubi, J.C.; Waser, B.; Friess, H.; Buchler, M.; Laissue, J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut, 1998, 42, 546-550.
52. Haberkorn, U.; Eisenhut, M.; Altmann, A.; Mier, W. Endoradiotherapy with peptides-status and future development. Curr. Med. Chem., 2008, 15, 219-234.
53. Garcia-Garayoa, E.; Maes, V.; Blauenstein, P.; Blanc, A.; Hohn, A.; Tourwé, D.; Schubiger, P.A. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumours. Nucl. Med. Biol., 2006, 33, 495-503.
54. 68Ga-labeled peptoid-peptide hybrid for imaging of neurotensin receptor expression in vivo. ACS Med. Chem. Lett., 2010, 1, 224-228.
55. Cheng, C.K.; Leung, P.C.K. Molecular biology of gonadotropinreleasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr. Rev., 2005, 26, 283-306.
56. Söderhäll, J.A.; Polymeropoulos, E.E.; Paulini, K.; Günther, E.; Kühne, R. Antagonist and agonist binding models of the human gonadotropin-releasing hormone receptor. Biochem. Biophys. Res. Commun., 2005, 333, 568-582.
57. Beckers, T.; Bernd, M.; Kutscher, B.; Kuhne, R.; Hoffmann, S.; Reissmann, T. Structure-function studies of linear and cyclized peptide antagonists of the GnRH receptor. Biochem. Biophys. Res. Commun., 2001, 289, 653-663.
58. Schally, A.V. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumourigenesis. Peptides, 1999, 20, 1247-1262.
59. Halmos, G.; Arencibia, J.M.; Schally, A.V.; Davis, R.; Bostwick, D.G. High Incidence of receptors for luteinizing hormone releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J. Urol., 2000, 163, 623-629.
60. Nagy, A.; Schally, A.V. Targeting of cytotoxic luteinizing hormonereleasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol. Reprod., 2005, 73, 851-859.
61. Harrison, G.S.; Wiermann, M.E.; Nett, T.M.; Glode, L.M. Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocrine-Related Cancer, 2004, 11, 725-748.
62. Barda, Y.; Cohen, N.; Lev, V.; Ben-Aroya, N.; Koch, Y.; Mishani, E.; Fridkin, M.; Gilon, C. Backbone metal cyclization: novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer. Nucl. Med. Biol., 2004, 31, 921-933.
63. Beckers, T.; Bernd, M.; Kutscher, B.; Kuhne, R.; Hoffmann, S.; Reissmann, T. Structure-Function Studies of linear and cyclized peptide antagonists of the GnRH receptor. Biochem. Biophys. Res. Commun., 2001, 289, 653-663.
64. Schottelius, M.; Berger, S.; Poethko, T.; Schwaiger, M.; Wester, H.-J. Development of novel Ga-68-and F-18-labeled GnRH-I analogues with high GnRHR-targeting efficiency. Bioconjugate Chem., 2008, 19, 1256-1268.
65. Spindel, E.R.; Giladi, E.; Segerson, T.P.; Nagalla, S. Bombesin-like peptides of ligands and receptors. Rec. Progr. Horm. Res., 1993, 48, 365-391.
66. Nagalla, S.R.; Barry, B.J.; Creswick, K.C.; Eden, P.; Taylor, J.T.; Spindel, E.R. Cloning of a receptor for amphibian [Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4). Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 6205-6209.
67. Schally, A.V.; Nagy, A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumours. Eur. J. Endocrinol., 1999, 141, 1-14.
68. Reubi, J.C.; Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 781-793.
69. Sancho, V.; Di Florio, A.; Moody, T.W.; Jensen, RT. Bombesin receptor-mediated imaging and cytotoxicity: review and current status. Curr. Drug Deliv., 2011, 8, 79-134.
70. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 247-258.
71. Garayoa, E.G.; Ruegg, D.; Blauenstein, P.; Zwimpfer, M.; Khan, I.U.; Maes, V.; Blanc, A.; Beck-Sickinger, A.G.; Tourwe, D.A.; Schubiger, P.A. Chemical and biological characterization of new Re(CO)(3)/(TC)-T-99m (CO)(3) bombesin analogues. Nucl. Med. Biol., 2007, 34, 17-28.
72. Weide, T.; Modlinger, A.; Kessler, H. Spatial screening for the identification of the bioactive conformation of integrin ligands. Top. Curr. Chem., 2007, 272, 1-50.
73. Knight, L.C. Radiolabeled peptide ligands for imaging thrombi and emboli. Nucl. Med. Biol., 2001, 28, 515-526.
74. 99mTc-RP128 as a potential inflammation imaging agent: human dosimetry and first clinical results. J. Nucl. Med., 2001, 42, 154-161.
75. Brooks, P.C. Role of integrins in angiogenesis. Eur. J. Cancer, 1996, 32A, 2423-2429.
76. Fiedler, W.; Graeven, U.; Ergun, S.; Verago, S.; Kilic, N.; Stockschlader, M.; Hossfeld, D.K. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 1997, 89, 1870-1875.
77. 99mTclabelled cyclic RGD pepticle for imaging the alpha-v-beta-3 expression. Nuklearmedizin, 2004, 43, 26-32.
78. 99mTc]HYNIC-RGD for imaging integrin alpha-vbeta-3 expression. Nucl. Med. Biol., 2006, 33, 945-952.
79. Sivolapenko, G.B.; Skarlos, D.; Pectasides, D.; Stathopoulou, E.; Milonakis, A.; Sirmalis, G.; Stuttle, A.; Courtenay-Luck, N.S.; Konstantinides, K.; Epenetos, A.A. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur. J. Nucl. Med., 1998, 25, 1383-1389.
80. Mas-Moruno, C.; Rechenmacher, F.; Kessler, H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem., 2010, 10, 753-768.
81. Miao, Y.B.; Whitener, D.; Feng, W.W.; Owen, N.K.; Cheng, J.Q.; Quinn, T.P. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjugate Chem., 2003, 14, 1177-1184.
82. 111In-DTPA-labeled analogs of alpha-melanocyte-stimulating hormone for melanoma targeting: receptor-binding in vitro and in vivo. Int. J. Cancer, 1994, 58, 749-755.
83. 188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl. Med. Biol., 1999, 26, 687-693.
84. 99mtechnetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res., 2000, 60, 5649-5658.
85. Raposinho, P.D.; Correia, J.o.D. G.; Oliveira, M.C.; Santos, I. Melanocortin-1 receptor-targeting with radiolabeled cyclic α-melanocyte-stimulating hormone analogs for melanoma imaging. Biopolymers, 2010, 94, 820-829.
86. Biondi, B.; Bolzati, C.; Carta, D.; Salvarese, N.; Refosco, F.; Calderan, A.; Ruzza, P. The Tc(N)PNP Metal Fragment Labeled Peptide for MC1 Receptors Imaging: preliminary studies. J. Pept. Sci., 2010, 16, 182.
87. Guo, H.; Yang, J.; Gallazzi, F.; Miao, Y. Reduction of the ring size of radiolabeled lactam bridge-cyclized α-MSH peptide, resulting in enhanced melanoma uptake. J. Nucl. Med., 2010, 51, 418-426.
88. 111In-labeled lactam bridge-cyclized a-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjugate Chem., 2008, 19, 539-547.
89. 111In-labeled lactam bridge-cyclized a-melanocytestimulating hormone peptide. Nucl. Med. Biol., 2009, 36, 267-276.
90. Hennig, I.M.; Laissue, J.A.; Horisberger, U.; Reubi, J.C. Substance-P receptors in human primary neoplasms: tumoural and vascular localization. Int. J. Cancer, 1995, 61, 786-792.
91. van Hagen, P.M.; Breeman, W.A.P.; Reubi, J.C.; Postema, P.T.E.; vanden Anker Lugtenburg, P.J.; Kwekkeboom, D.J.; Laissue, J.; Waser, B.; Lamberts, S.W.J.; Visser, T.J.; Krenning, E.P. Visualization of the thymus by substance P receptor scintigraphy in man. Eur. J. Nucl. Med., 1996, 23, 1508-1513.
92. Gotthardt, M.; Fischer, M.; Naeher, I.; Holz, J.B.; Jungclas, H.; Fritsch, H.W.; Behe, M.; Goke, B.; Joseph, K.; Behr, T.M. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 597-606.
93. Reubi, J.C.; Gugger, M.; Waser, B.; Schaer, J.C. Y(1)mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res., 2001, 61, 4636-4641.
94. Korner, M.; Waser, B.; Reubi, J.C. High expression of neuropeptide Y receptors in tumours of the human adrenal gland and extra-adrenal paraganglia. Clin. Cancer Res., 2004, 10, 8426-8433.
95. Langer, M.; La Bella, R.; Garcia-Garayoa, E.; Beck-Sickinger, A.G. 99mTc-labeled neuropeptide Y analogues as potential tumour imaging agents. Bioconjugate Chem., 2001, 12, 1028-1034.
96. Khan, I.U.; Zwanziger, D.; Bohme, I.; Javed, M.; Naseer, H.; Hyder, S.W.; Beck-Sickinger, A.G. Breast-Cancer Diagnosis by Neuropeptide Y Analogues: From Synthesis to Clinical Application. Angew. Chem.-Int. Edit., 2010, 49, 1155-1158.
97. Zaidi, M.; Moonga, B.S.; Bevis, P.J.R.; Bascal, Z.A.; Breimer, L.H. The calcitonin gene peptides: biology and clinical relevance. Crit. Rev. Clin. Lab. Sci., 1990, 28, 109-174.
98. Reubi, J.C. Neuropeptide receptors in health and disease: the molecular-basis for in vivo imaging. J. Nucl. Med., 1995, 36, 1825-1835.
99. Wester, H.J.; Koglin, N.; Schwaiger, M.; Kessler, H.; Laufer, B.; Demmer, O.; Anton, M. Cancer imaging and treatment. Int. Appl. WO 2007096662 (2007).
100. Fujii, N.; Oishi, S.; Hiramatsu, K.; Araki, T.; Ueda, S.; Tamamura, H.; Otaka, A.; Kusano, S.; Terakubo, S.; Nakashima, H.; Broach, J.A.; Trent, J. O.; Wang, Z.-x.; Peiper, S. Molecular-Size Reduction of a Potent CXCR4-Chemokine Antagonist Using Orthogonal Combination of Conformation-and Sequence-Based Libraries. Angew. Chem.-Int. Edit., 2003, 42, 3251-3253.
101. Wester, H.J.; Kessler, H.; Demmer, O.; Dijkgraaf, I. Cancer imaging and treatment. US 2010/0240072 A1 (2010).
102. Reubi, J.C. In Radionuclide peptide cancer therapy. Chinol M., Paganelli G., Eds., Taylor & Francis: New York (NY) 2006, 31-39.
103. Mitra, A.; Nan, A.; Papadimitriou, J.C.; Ghandehari, H.; Line, B.R. Polymer-peptide conjugates for angiogenesis targeted tumour radiotherapy. Nucl. Med. Biol., 2006, 33, 43-52.
104. Dijkgraaf, I.; Kruijtzer, J.A. W.; Liu, S.; Soede, A.C.; Oyen, W.J.G.; Corstens, F.H.M.; Liskamp, R.M.J.; Boerman, O.C. Improved targeting of the alpha(v)beta(3) integrin by multimerisation of RGD peptides. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 267-273.
105. Li, Z.B.; Chen, K.; Chen, X. Ga-68-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta(3) expression. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1100-1108.
106. Liu, S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta (3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjugate Chem., 2009, 20, 2199-2213.
107. Thumshirn, G.; Hersel, U.; Goodman, S.L.; Kessler, H. Multimeric cyclic RGD peptides as potential tools for tumour targeting: Solidphase peptide synthesis and chemoselective oxime ligation. Chem.-Eur. J., 2003, 9, 2717-2725.
108. Poethko, T.; Schottelius, M.; Thumshim, G.; Hersel, U.; Herz, M.; Henriksen, G.; Kessler, H.; Schwaiger, M.; Wester, H.J. Two-step methodology for high-yield routine radiohalogenation of peptides: F-18-labeled RGD and octreotide analogs. J. Nucl. Med., 2004, 45, 892-902.
109. Poethko, T.; Schottelius, M.; Thumshirn, G.; Herz, M.; Haubner, R.; Henriksen, G.; Kessler, H.; Schwaiger, M.; Wester, H.J. Chemoselective pre-conjugate radiohalogenation of unprotected mono-and multimeric peptides via oxime formation. Radiochim. Acta, 2004, 92, 317-327.
110. Chen, X.Y.; Liu, S.; Hou, Y.P.; Tohme, M.; Park, R.; Bading, J.R.; Conti, P.S. MicroPET imaging of breast cancer alpha(v)-integrin expression with Cu-64-labeled dimeric RGD peptides. Mol. Imaging. Biol., 2004, 6, 350-359.
111. Wu, Y.; Zhang, X.Z.; Xiong, Z.M.; Cheng, Z.; Fisher, D.R.; Liu, S.; Gambhir, S.S.; Chen, X.Y. MicroPET imaging of glioma integrin alpha(V)beta(3) expression using Cu-64-labeled tetrameric RGD peptide. J. Nucl. Med., 2005, 46, 1707-1718.
112. Liu, S.; Kim, Y.S.; Hsieh, W.Y.; Sreerama, S.G. Coligand effects on the solution stability, biodistribution and metabolism of the Tc-99m-labeled cyclic RGDfK tetramer. Nucl. Med. Biol., 2008, 35, 111-121.
113. Jia, B.; Liu, Z.; Shi, J.; Yu, Z.; Yang, Z.; Zhao, H.; He, Z.; Liu, S.; Wang, F. Linker effects on biological properties of In-111-labeled DTPA conjugates of a cyclic RGDfK dimer. Bioconjugate Chem., 2008, 19, 201-210.
114. Wang, J.J.; Kim, Y.S.; Liu, S. (99m)Tc-labeling of HYNICConjugated cyclic RGDfK dimer and tetramer using EDDA as coligand. Bioconjugate Chem., 2008, 19, 634-642.
115. Janssen, M.; Oyen, W. J.G.; Massuger, L.; Frielink, C.; Dijkgraaf, I.; Edwards, D.S.; Radjopadhye, M.; Corstens, F.H. M.; Boerman, O.C. Comparison of a monomeric and dimeric radiolabeled RGDpeptide for tumour targeting. Cancer Biother. Radiopharm., 2002, 17, 641-646.
116. Li, Z.B.; Cai, W.B.; Cao, Q.Z.; Chen, K.; Wu, Z.H.; He, L.N.; Chen, X.Y. 64Cu-Labeled Tetrameric and octameric RGD peptides for small-animal PET of tumour alpha(v)beta(3) integrin expression. J. Nucl. Med., 2007, 48, 1162-1171.
117. Wang, L.J.; Shi, J. Y.; Kim, Y.S.; Zhai, S.Z.; Jia, B.; Zhao, H.Y.; Liu, Z.F.; Wang, F.; Chen, X.Y.; Liu, S. Improving tumourtargeting capability and pharmacokinetics of Tc-99m-labeled cyclic RGD dimers with PEG(4) linkers. Mol. Pharm., 2009, 6, 231-245.
118. 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J. Med. Chem., 2008, 51, 7980-7990.
119. McNerny, D.Q.; Kukowska-Latallo, J.F.; Mullen, D.G.; Wallace, J.M.; Desai, A.M.; Shukla, R.; Huang, B.H.; Holl, M.M.B.; Baker, J.R. RGD dendron bodies; synthetic avidity agents with defined and potentially interchangeable effector sites that can substitute for antibodies. Bioconjugate Chem., 2009, 20, 1853-1859.
120. Line, B.R.; Mitra, A.; Nan, A.; Ghandehari, H. Targeting tumour angiogenesis: comparison of peptide and polymer-peptide conjugates. J. Nucl. Med., 2005, 46, 1552-1560.
121. Carlson, C.B.; Mowery, P.; Owen, R.M.; Dykhuizen, E.C.; Kiessling, L.L. Selective tumour cell targeting using low-affinity, multivalent interactions. ACS Chem. Biol., 2007, 2, 119-127.
122. Yang, J.Q.; Guo, H.X.; Gallazzi, F.; Berwick, M.; Padilla, R.S.; Miao, Y. Evaluation of a novel Arg-Gly-Asp-conjugated alphamelanocyte stimulating hormone hybrid peptide for potential melanoma therapy. Bioconjugate Chem., 2009, 20, 1634-1642.
123. Yang, J.; Guo, H.; Miao, Y. Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging. Nucl. Med. Biol., 2010, 37, 873-883.
124. Liu, Z.F.; Li, Z.B.; Cao, Q.Z.; Liu, S.; Wang, F.; Chen, X. Smallanimal PET of tumours with (64Cu)-labeled RGD-Bombesin heterodimer. J. Nucl. Med., 2009, 50, 1168-1177.
125. Liu, Z.F.; Niu, G.; Wang, F.; Chen, X. Ga-68-labeled NOTA-RGDBBN peptide for dual integrin and GRPR-targeted tumour imaging. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36, 1483-1494.
126. Liu, Z.F.; Yan, Y.J.; Chin, F.T.; Wang, F.; Chen, X. Dual integrin and gastrin-releasing peptide receptor targeted tumour imaging using F-18-labeled PEGylated RGD-Bombesin heterodimer F-18-FB-PEG(3)-Glu-RGD-BBN. J. Med. Chem., 2009, 52, 425-432.
127. Monaghan, S.; Griffith-Johnson, D.; Matthews, I.; Bradley, M. Solid-phase synthesis of peptide-dendrimer conjugates for an investigation of integrin binding. Arkivoc, 2001, 2, 46-53.
128. Stukel, J.M.; Li, R.C.; Maynard, H.D.; Caplan, M.R. Twostep synthesis of multivalent cancer-targeting constructs. Biomacromolecules, 2010, 11, 160-167.
129. Rosca, E.V.; Gillies, R.J.; Caplan, M.R. Glioblastoma targeting via integrins is concentration dependent. Biotechnol. Bioeng., 2009, 104, 408-417.
130. Yim, C.B.; Dijkgraaf, I.; Merkx, R.; Versluis, C.; Eek, A.; Mulder, G.E.; Rijkers, D.T.S.; Boerman, O.C.; Liskamp, R.M.J. Synthesis of DOTA-conjugated multimeric Tyr(3) octreotide peptides via a combination of Cu(I)-catalyzed "click" cycloaddition and thio acid/sulfonyl azide "sulfo-click" amidation and their in vivo evaluation. J. Med. Chem., 2010, 53, 3944-3953.
131. Handl, H.L.; Sankaranarayanan, R.; Josan, J.S.; Vagner, J.; Mash, E. A.; Gillies, R.J.; Hruby, V.J. Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjugate Chem., 2007, 18, 1101-1109.
132. Vagner, J.; Xu, L.P.; Handl, H.L.; Josan, J.S.; Morse, D.L.; Mash, E.A.; Gillies, R J.; Hruby, V.J. Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew. Chem.-Int. Edit., 2008, 47, 1685-1688.
133. Josan, J.S.; Vagner, J.; Handl, H.L.; Sankaranarayanan, R.; Gillies, R.J.; Hruby, V.J. Solid-phase synthesis of heterobivalent ligands targeted to melanocortin and cholecystokinin receptors. Int. J. Pept. Res. Ther., 2008, 14, 293-300.
134. Xu, L.; Vagner, J.; Josan, J.; Lynch, R.M.; Morse, D.L.; Baggett, B.; Han, H.; Mash, E.A.; Hruby, V.J.; Gillies, R.J. Enhanced targeting with heterobivalent ligands. Mol Cancer Ther., 2009, 8, 2356-2365.
135. Yamamoto, T.; Nair P.; Largent-Milnes, T.M.; Jacobsen, N.E.; Davis, P.; Ma, S.W.; Yamamura, H.I.; Vanderah, T.W.; Porreca, F.; Lai, J.; Hruby, V.J. Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-l-tyrosine: in vitro, in vivo, and NMR-based structural studies. J. Med. Chem., 2011, 54, 2029-2038.
136. Bapst, J.-P.; Froidevaux, S.; Calame, M.; Tanner, H.; Eberle, A.N. Dimeric DOTA-alpha-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity. J. Recept. Signal Transduct., 2007, 27, 383-409.
137. Falciani, C.; Brunetti, J.; Pagliuca, C.; Menichetti, S.; Vitellozzi, L.; Lelli, B.; Pini, A.; Bracci, L. Design and in vitro evaluation of branched peptide conjugates: turning nonspecific cytotoxic drugs into tumour-selective agents. ChemMedChem, 2010, 5, 567-574.
138. Tweedle, M. F. Peptide-targeted diagnostics and radiotherapeutics. Accounts Chem. Res., 2009, 42, 958-968.
139. Khandare, J.J.; Chandna, P.; Wang, Y.; Pozharov, V.P.; Minko, T. Novel polymeric prodrug with multivalent components for cancer therapy. J. Pharmacol. Exp. Ther., 2006, 317, 929-937.
140. Ding, H.; Prodinger, W.M.; Kopecek, J. Identification of CD21-binding peptides with phage display and investigation of binding properties of HPMA copolymer-peptide conjugates. Bioconjugate Chem., 2006, 17, 514-523.
141. Reczek, J.J.; Kennedy, A.A.; Halbert, B.T.; Urbach, A.R. Multivalent recognition of peptides by modular self-assembled receptors. J. Am. Chem. Soc., 2009, 131, 2408-2415.
142. Krenning, E.P.; Breeman, W. A.P.; Kooij, P.P. M.; Lameris, J.S.; Bakker, W.H.; Koper, J.W.; Ausema, L.; Reubi, J.C.; Lamberts, S.W.J. Localization of Endocrine-Related Tumours with Radioiodinated Analog of Somatostatin. Lancet, 1989, 1, 242-244.
143. Ruzza, P.; Calderan, A. Radiolabeled peptide-receptor ligands in tumour imaging. Expert Opin. Med. Diagn., 2011, 5, 411-424.